Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prenoxdiazine is a small molecule antitussive (cough suppressant) used primarily for the symptomatic relief of dry, nonproductive coughs, especially those of bronchial origin. It acts peripherally by desensitizing pulmonary stretch receptors in the respiratory tract, thereby reducing cough impulses originating from the lungs. Unlike centrally acting antitussives, it does not suppress the cough center in the brain but works at peripheral sites to decrease tussal (cough) reflex sensitivity. It is typically administered orally and is available as tablets or syrup. Common side effects include mild sedation, dizziness, nausea, constipation, and dry mouth[1][2][5][7]. There is no evidence of teratogenic risk when used during pregnancy[6][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prenoxdiazine.